Cefalotin

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefalotin is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1974. DrugCentral lists 8 molecular targets, including SLC22A8, SLC22A11 and PTPN7. Recorded indications include Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Female genital tract infection and Genitourinary Tract Infections.

• Approval status: ofm (first approved 1974 by the FDA).
• Molecular targets: SLC22A8, SLC22A11, PTPN7 and PTGS2 (8 listed in DrugCentral).
• Indications: Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Female genital tract infection, Genitourinary Tract Infections and Haemophilus influenzae pneumonia and others.
• ATC code: J01DB03 (First-generation cephalosporins).
• Molecular formula: C16H16N2O6S2; molecular weight 396.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (13)

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial septicemia
• Female genital tract infection
• Genitourinary Tract Infections
• Haemophilus influenzae pneumonia
• Infection of bone
• Infection of skin AND/OR subcutaneous tissue
• Infectious disorder of joint
• Lower respiratory tract infection
• Pneumonia
• Pneumonia due to Streptococcus
• Prevention of Perioperative Infection
• Urinary tract infectious disease

Mechanism & targets

Molecular targets (8)

Target	Gene	Action	Activity
Solute carrier family 22 member 8	SLC22A8	inhibitor	IC50 7.59
Solute carrier family 22 member 11	SLC22A11	inhibitor	Ki 6.70
Tyrosine-protein phosphatase non-receptor type 7	PTPN7	unknown	IC50 6.04
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 4.70
Matrix metalloproteinase-9	MMP9	unknown	IC50 4.66
Somatostatin receptor type 4	SSTR4	unknown	IC50 4.40
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1974-12-18	FDA	—	LILLY

ATC classification

ATC code	Therapeutic hierarchy
J01DB03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › First-generation cephalosporins

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cefalotin is on its molecule page.

• Molecular formula: C₁₆H₁₆N₂O₆S₂
• Molecular weight: 396.45 g/mol
• CAS number: —
• InChIKey: XIURVHNZVLADCM-IUODEOHRSA-N
• PubChem CID: 6024

CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CC=CS1)C2=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefalotin used for?

DrugCentral lists the following indications for Cefalotin: Bacterial infection due to Klebsiella pneumoniae, Bacterial septicemia, Female genital tract infection, Genitourinary Tract Infections, Haemophilus influenzae pneumonia, Infection of bone, Infection of skin AND/OR subcutaneous tissue and Infectious disorder of joint and others.

How does Cefalotin work?

Its molecular targets in DrugCentral include SLC22A8 (inhibitor), SLC22A11 (inhibitor), PTPN7 and PTGS2.

When was Cefalotin first approved?

Cefalotin was first approved by the FDA in 1974.

What is the chemical formula of Cefalotin?

Cefalotin has the molecular formula C16H16N2O6S2 and a molecular weight of 396.45 g/mol.

Sources

• DrugCentral drug card 574 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1632 — compound record and bioactivity
• PubChem CID 6024 — chemical identifiers
• DrugBank DB00456 — drug record
• FDA UNII C22G6EYP8B — substance identity
• DailyMed: FDA labels for Cefalotin — current prescribing information (label search)
• UniProt Q8TCC7 (SLC22A8) — target protein
• UniProt Q9NSA0 (SLC22A11) — target protein
• UniProt P35236 (PTPN7) — target protein
• UniProt P35354 (PTGS2) — target protein
• UniProt P14780 (MMP9) — target protein
• UniProt P31391 (SSTR4) — target protein

How this page is built: methodology · editorial policy & corrections.